Rokszin et al. showed that SGLT-2i had a late risk reduction in some types of cancer, including breast, lower gastrointestinal tract, and lung cancers.75 In addition, reviews of RCTs included other users of SGLT-2, including patients with heart failure and chronic kidney disease. This evidence concerns the gene SLC5A2 and lung carcinoma.